Clinical Trial: A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917481) titled 'A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma' on Oct. 26.

Brief Summary: This trial will study the most common type of advanced liver cancer, hepatocellular carcinoma (HCC). Participants will be treated with ivonescimab, a drug targeting immune cells and blood vessels in tumors, which has proven efficacy in treating lung cancer. The main purpose of the Study is to analyze the efficacy of ivonescimab in participants who have advanced HCC. Ivonescimab efficacy will be determined by assessing the period from ivonescimab treatment initiation...